Literature DB >> 15888510

Effects of lorazepam on fear-potentiated startle responses in man.

S J Graham1, J C Scaife, R W Langley, C M Bradshaw, E Szabadi, L Xi, T Crumley, N Calder, K Gottesdiener, J A Wagner.   

Abstract

Sudden intense sensory stimuli elicit a cascade of involuntary responses, including a short-latency skeletal muscular response ('eyeblink startle response') and longer-latency autonomic responses. These responses are enhanced when subjects anticipate an aversive event compared to periods when subjects are resting ('fear potentiation'). It has been reported previously that the anxiolytic diazepam can suppress fear-potentiation of the eyeblink startle response in human volunteers. The present experiment aimed to confirm and extend these observations by examining the effect of another benzodiazepine, lorazepam, on the eyeblink and skin conductance components of the acoustic startle, and on fear-potentiation of these responses. Eighteen male volunteers participated in three weekly sessions in which they received oral treatment with placebo, lorazepam (1 mg) and lorazepam (2 mg), according to a balanced three-period, crossover, double-blind design. Two hours after ingestion of the treatments, electromyographic responses of the orbicularis oculi muscle and skin conductance responses were evoked by sound pulses during alternating periods in which the threat of an electric shock (electrodes attached to the subject's wrist) was present (THREAT) and absent (SAFE). The THREAT condition was associated with significant increase in the amplitude of the electromyographic (EMG) and skin conductance responses; there were also increases in baseline skin conductance, the number and amplitude of 'spontaneous' skin conductance fluctuations and self-rated anxiety. Lorazepam attenuated the effect of THREAT on self-rated anxiety and on the amplitude of the EMG response, but had no significant effect on fear-potentiation of the skin conductance responses. These results extend previous findings of the effect of diazepam on the fear-potentiated eyeblink startle response to lorazepam, and suggest that fear-potentiation of the later autonomic component of the startle response may be less sensitive to benzodiazepines than the fear-potentiated eyeblink response and self-rated anxiety.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888510     DOI: 10.1177/0269881105051528

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  12 in total

1.  Emotion regulation and potentiated startle across affective picture and threat-of-shock paradigms.

Authors:  Shmuel Lissek; Kaebah Orme; Dana J McDowell; Linda L Johnson; David A Luckenbaugh; Johanna M Baas; Brian R Cornwell; Christian Grillon
Journal:  Biol Psychol       Date:  2007-07-13       Impact factor: 3.251

2.  Phasic and sustained fear are pharmacologically dissociable in rats.

Authors:  Leigh Miles; Michael Davis; David Walker
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

3.  Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans.

Authors:  Floris Klumpers; Damiaan Denys; J Leon Kenemans; Christian Grillon; Jasper van der Aart; Johanna M P Baas
Journal:  J Psychopharmacol       Date:  2012-02-20       Impact factor: 4.153

4.  Psychometric evaluation of a visual analog scale for the assessment of anxiety.

Authors:  Valerie S L Williams; Robert J Morlock; Douglas Feltner
Journal:  Health Qual Life Outcomes       Date:  2010-06-08       Impact factor: 3.186

Review 5.  Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety.

Authors:  Michael Davis; David L Walker; Leigh Miles; Christian Grillon
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

6.  The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects.

Authors:  Martin Siepmann; Benjamin Heine; Andreas Kluge; Tjalf Ziemssen; Michael Mück-Weymann; Wilhelm Kirch
Journal:  Clin Auton Res       Date:  2007-03-27       Impact factor: 4.435

7.  Modelling anxiety in humans for drug development.

Authors:  Martin Siepmann; Peter Joraschky
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

Review 8.  Assessing anxiety in nonhuman primates.

Authors:  Kristine Coleman; Peter J Pierre
Journal:  ILAR J       Date:  2014

9.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

10.  Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine.

Authors:  J M P Baas; N Mol; J L Kenemans; E P Prinssen; I Niklson; C Xia-Chen; F Broeyer; J van Gerven
Journal:  Psychopharmacology (Berl)       Date:  2009-05-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.